Approximately 20 million people in the United States are currently affected by chronic kidney disease (CKD), with half a million of these presenting with the most severe form -end-stage renal disease (ESRD). The only treatments for ESRD are dialysis or transplantation. However, the mortality rate of patients on dialysis can be as high as 20% per year 1, 2 , and transplantation is limited by organ shortage. The most common cause of chronic and ESRD in the United States is diabetes, which accounts for roughly 50% of all cases, followed by hypertension (25%), with other causes including glomerulonephritides and polycystic kidney disease 1, 3 . Cardiovascular disease remains the leading cause of mortality in patients with CKD 4 . Despite tremendous progress in reducing deaths from cardiovascular disease in the general population, this has not translated to CKD patients. The reduction in cardiovascular disease in the general population correlates strongly with reduced serum cholesterol levels, smoking and blood pressure, but the mortality rate of individuals with CKD is much higher than that of individuals without CKD when compared by traditional cardiovascular disease risk calculations 5, 6 . 'Non-traditional' risk factors may result from the build-up of different toxins and metabolites, which probably contributes to this increased mortality rate in CKD patients.
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The most commonly used definition for CKD is purely based on estimation of the glomerular filtration rate (eGFR) 7 , with a 40% decline in GFR (to a GFR of less than 60 ml per min per 1.73 m 2 ) for more than 3 months being used to diagnose CKD. Different stages of CKD have been proposed based on GFR criteria. These criteria include: stage G1, when the GFR is greater than 90 ml per min; stage G2, when the GFR is 60-90 ml per min; stage G3, when the GFR is 30-60 ml per min; stage G4, when the GFR is 15-30 ml per min; and stage G5, when the GFR is below 15 ml per min. These stages were developed mostly for research purposes, and at present we are not aware of any clear distinction between them; rather, GFR decline represents a continuously increased risk for death. A broader definition of CKD is also in use, which takes structural, functional and imaging abnormalities into consideration. Leakage of albumin or protein into the urine is one such functional abnormality that has gained more prominence in the new classification guidelines 8, 9 . Most clinical studies use albuminuria and proteinuria interchangeably, as albumin and its degradation products represent the overwhelming majority of urinary proteins. The presence of albuminuria correlates strongly with the development of ESRD, increased cardiovascular disease and mortality, whereas the reduction of albuminuria is usually associated with protection from functional decline 10 . Sclerosis of the glomerulus and interstitial fibrosis are common histopathological and structural features of CKD 11 . Glomerular changes are usually specific for disease aetiology and, as indicated above, are therefore used for diagnosis and disease classification 12 . Tubulointerstitial fibrosis strongly correlates with kidney function and represents a common complex architectural change in the kidney 11, 13 , which includes matrix and collagen production by epithelial cells and activated myofibroblasts 11 . Mouse genetic studies have highlighted the key role of epithelial cells in the development of fibrosis [14] [15] [16] . Indeed, genetic overexpression of Notch, WNT, kidney injury molecule 1 (KIM1) and hypoxia-inducible factor 1 (HIF1) in tubule epithelial cells was sufficient to induce epithelial damage, dedifferentiation and the full spectrum of fibrosis [14] [15] [16] , whereas the genetic deletion of these pathways protected from fibrosis development. Fibrosis is a reactive process that develops mostly in response to epithelial injury and is almost always accompanied by inflammation, which is manifested by increased cytokine expression and accumulation of macrophages and inflammatory cells 17 . Vascular injury and loss of capillaries exacerbate epithelial injury at later stages of the disease, by limiting the nutrient availability to epithelial cells. Our understanding of fibrosis has greatly improved over the past several years, revealing new potential therapeutic targets.
At present, there is no cure for most forms of CKD. The list of conditions associated with reversible renal failure is short, comprising decreased renal perfusion, nephrotoxic drugs and urinary obstruction. Although steroids and other immunosuppressive measurements can halt or reverse some diseases of the kidney -such as immunoglobulin A (IgA) nephropathy 18 , lupus nephritis, membranous nephropathy, focal segmental glomerulosclerosis, vasculitis and minimal change disease -they have not shown benefit in kidney disease in patients with diabetes and hypertension 19 .
Haemodynamic changes have a crucial role in CKD development, and strategies to control high blood pressure have had a substantial beneficial impact on this disease 20 . An increase in systemic blood pressure can increase glomerular filtration, leading to hyperfiltration and an increase in glomerular size, and glomerular cells must endure the increased stretch 21 . In addition, as the vessels that supply the kidney with nutrients originate from the efferent portion of the glomerulus, these changes reduce the post-glomerular blood flow leading to ischaemic changes in the kidney 22, 23 . Inhibiting the renin-angiotensin system (RAS), which is involved in the regulation of blood pressure and fluid balance 19 , using either angiotensin-converting enzyme inhibitors (ACEIs) or type 1 angiotensin II receptor blockers (ARBs), reduces glomerular hyperfiltration and albuminuria and slows the decline in kidney function 19 . These agents have therefore become the mainstay of CKD treatment. However, this approach only slows the decline in kidney function and does not cure CKD. In addition, these agents can be associated with serious side effects, such as an increase in serum potassium levels, which can limit their therapeutic use 24 .
There are several additional drugs in development that target haemodynamic changes in CKD. Smoking cessation also slows the rate of progression 25 . Many practitioners recommend protein restriction, statin therapy and the correction of metabolic acidosis, but at present the benefits of these measures have not been unequivocally demonstrated in large randomized trials 26 . As our understanding of the pathogenic mechanisms of CKD has improved, new therapeutic approaches, including targeting inflammation, fibrosis or podocytes, are emerging. In this Review, we assess current and emerging strategies for the treatment of the major types of CKD -diabetic and hypertensive CKD -and address key challenges and considerations in the development of novel therapies and future clinical trial design.
Current treatments for CKD ACE inhibition and type 1 angiotensin II receptor (AT 1 ) blockade have been the mainstays of therapy for CKD for more than 20 years (FIG. 1) . The initial rationale for testing ACEI therapy was based on preclinical studies that showed a reduction in intraglomerular haemodynamic pressure accompanied by reduction of proteinuria in hyperfiltering rat models of kidney disease, including diabetic nephropathy and partial renal ablation 23, 27 . Clinical testing of the ACEI captopril in patients with type 1 diabetes and nephropathy revealed that captopril improved renal outcomes beyond those that were achieved with alternative methods of blood pressure reduction 28 , establishing captopril and ACEIs as the standard of care for patients with diabetic nephropathy. Subsequent studies extended the observed benefit to patients with other causes of kidney disease, including those with late-stage CKD 29, 30 . Similar beneficial effects of AT 1 blockade were subsequently observed in patients with type 2 diabetes and nephropathy [31] [32] [33] , establishing the RAS as a key target for the treatment of CKD. Notably, the therapeutic benefit of ACEIs and ARBs is closely associated with an early reduction in eGFR 34 coupled with a reduction in proteinuria (or albuminuria) 35, 36 (FIG. 1) , which is consistent with the capacity of these agents to reduce intraglomerular filtration pressure as noted above 27 . However, although ACEIs and ARBs slow the progression of renal disease, they do not halt it. In addition, such therapies have been associated with side effects -including cough (for ACE inhibition) and serious hyperkalaemia -that often limit their use 37, 38 . Although the introduction of ACEI and ARB therapy has decreased the incidence of renal failure in the United States 1 , the prevalence of CKD has increased, with more than 100,000 individuals developing renal failure each year 1, 39 . Furthermore, the dramatic decrease in adverse cardiovascular outcomes, stroke and amputations seen over the past 20 years in diabetes patients has not been accompanied by a similar reduction in diabetic ESRD 39 . At present, there are no therapies that reverse the loss of renal function in CKD, in stark contrast to more-acute inflammatory glomerulonephritis, in which immunosuppression can treat and potentially even cure the disease.
Nevertheless, ACEIs and ARBs are now considered the standard of care for chronic proteinuric kidney disease; therefore, any novel therapy must prove added benefit on the background of ACEI or ARB therapy.
Modulating renal haemodynamics
Combining ACEI and ARB therapy. Given the evident role of the RAS in the progression of renal disease, it was hypothesized that continued disease progression could be prevented by more complete RAS blockade 38, 40 . To investigate this, several trials investigating the combination of an ACEI and an ARB have been performed.
The ONTARGET trial compared the benefit of the ACEI ramipril, the ARB telmisartan and their combination in 25,920 patients with vascular disease and/or high-risk diabetes 41 . Notably, most of the patients enrolled in ONTARGET did not have microalbuminuria or macroalbuminuria at baseline, so renal benefit afforded by combination ACEI-ARB therapy in patients with proteinuria could not be established 41 . During the study, 784 patients permanently discontinued randomized therapy because of hypotensive symptoms, with the majority of these being on combination therapy. The number of patients achieving primary renal outcome of dialysis, doubling of serum creatinine or death was significantly increased in the combination therapy group compared with those treated with monotherapy. Many of the dialysis events were due to acute renal failure, which was particularly increased in normotensive patients. These disappointing, but not entirely unpredictable, results underscore the safety risks associated with ACEI-ARB therapy.
Similarly, the VA NEPHRON-D trial investigated whether the combination of an ACEI and an ARB (lisinopril and losartan, respectively) further improved renal outcomes in patients with type 2 diabetes mellitus, but this study only enrolled patients with substantial residual proteinuria 37 . Upon enrolment, patients were all placed on losartan. During the initial up-titration of losartan, there was a significant decline in the median urinary albumin/creatinine ratio (UACR). Patients were then randomized to additionally receive either lisinopril or placebo. In the year following randomization, a further decline in albuminuria was observed, which was significantly greater in the combination therapy group compared with patients receiving monotherapy. Although there was a trend towards reduced renal failure events using the ACEI-ARB combination, this was not statistically significant. Moreover, the combination was associated with doubling of the risk for hyperkalaemia and acute kidney injury compared to monotherapy 37 . Based on these results, combination ACEI-ARB therapy cannot be widely recommended for use in clinical practice, although fastidious management of serum potassium might allow this combination to provide some benefit for select patients with residual proteinuria 37 .
Renin inhibition. An alternative approach to RAS blockade is to inhibit the first step in the renin-angiotensinaldosterone cascade: renin-mediated cleavage of angiotensinogen to angiotensin 1 (FIG. 1) . The effect of the renin inhibitor aliskiren on renal outcomes was tested in patients with diabetic nephropathy (the ALTITUDE trial) 42 . Aliskiren added to either ACEI or ARB therapy resulted in greater albuminuria reduction than placebo, but did not decrease renal events or improve the rate of eGFR loss and was associated with increased hyperkalaemia and stroke. The ALTITUDE trial was prematurely terminated owing to increased adverse events and lack of benefit on renal function decline. Taken together, these findings raise serious concerns regarding the safety of complete RAS inhibition as a strategy for treating progressive renal disease.
Mineralocorticoid receptor antagonists.
The mineralocorticoid aldosterone is an important mediator of the effect of angiotensin, as angiotensin causes aldosterone to be released from the adrenal gland (FIG. 1) . Aldosterone increases tubule secretion of potassium and reabsorption of sodium and chloride, thereby expanding intravascular volume and increasing blood pressure 43 . Aldosterone also plays a part in directly regulating the expression of several profibrotic molecules, such as plasminogen activator inhibitor 1 . Despite the preceding findings for the ACEI-ARB combination and the known risks of hyperkalaemia following mineralocorticoid receptor blockade 47 , trials of mineralocorticoid receptor inhibitors for the treatment of diabetic nephropathy are underway. An open-label study investigating the aldosterone receptor antagonist spironolactone plus ARB, versus ACEI-ARB, suggested that there is superior UACR reduction in patients with microalbuminuria and diabetic nephropathy taking spironolactone 48 , although the interpretation was confounded by lower blood pressures in this group 49 . Additional studies of mineralocorticoid receptor antagonists are ongoing and include efficacy studies of finerenone (Bayer) 50 , CS-3150 (Daiichi-Sankyo) and MT-3995 (Mitsubishi Tanabe) to determine the effects of these agents on the UACR in patients with diabetic nephro pathy 51 . Whether appropriate dosing regimens can be identified that will provide efficacy but circumvent the risk of hyperkalaemia remains to be seen. It seems, however, that approaches that target pathways orthogonal to the renin-angiotensin-aldosterone system should have the advantage of non-overlapping safety profile concerns. Targeting the vasculature Diabetic kidney disease is grouped under the microvascular complications of diabetes. Endothelial cell dysfunction, including proliferation and abnormal angiogenesis, can be observed in both experimental diabetes and human disease 52 . Similar endothelial pathology has been reported in the retina, which probably underlies the strong association between renal disease and retin opathy in diabetes 53, 54 . Early phases of experimental diabetes are characterized by an increase in glomerular size, which may be a consequence of cellular endothelial hypertrophy and hyperplasia, as well as podocyte hypertrophy 55, 56 ( FIG. 2) . Podocytes are a rich source of vascular endothelial growth factor (VEGF), angiopoietins and stromal The boxes to the right of and below this panel illustrate the different abnormalities observed in chronic kidney disease (CKD) and potential therapeutic strategies and agents to target them. For endothelial cells, these abnormalities include: loss of glycocalyx (targeted by sulodexide), increased endothelin 1 (ET1) signalling (blocked by atrasentan), decreased vascular endothelial growth factor (VEGF) expression, and increased CD80 expression (targeted by abatacept). For podocytes, these abnormalities include: podocyte loss by detachment and apoptosis (targeted by reactive oxygen species (ROS) inhibitors, focal adhesion kinase 1 (FADK1) inhibitors or integrin inhibitors), increased dynamin oligomerization and cytoskeletal changes (targeted by Bis-T-23), podocyte hypertrophy by increased mechanistic target of rapamycin (mTOR) and liver kinase B1 (LKB1) activity (targeted by rapamycin), and podocyte dedifferentiation by increased WNT and Notch signalling (targeted by lithium and γ-secretase inhibitors (GSIs)). b | Periodic acid-Schiff (PAS)-stained kidney sections from a patient with diabetic glomerulosclerosis. Note the increased pink matrix materials, indicative of glomerulosclerosis, and the obliterated glomerular capillaries.
cell-derived factor 1 (SDF1), generating a bidirectional signalling pathway between endothelial and glomerular epithelial cells across the filtration barrier 57 (FIG. 2) . This podocyte-endothelial crosstalk plays a pivotal part in mediating filtration barrier permselectivity and albuminuria development 58 . The interaction between podocytes and endothelial cells has been the focus of robust preclinical experimentation, but most targets have not yet advanced into clinical development.
Restoring the endothelial glycocalyx. The glycocalyx is a glycoprotein-and polysaccharide-rich coat that covers mammalian cells (FIG. 2) . Glomerular endothelial glycocalyx protects from proteinuria by limiting the entry of plasma proteins into the filtration barrier 59, 60 . Perturbation and loss of the endothelial glycocalyx has been proposed to be an early event in diabetes 61, 62 . Sulodexide is a highly purified mixture of glycosaminoglycans, composed of 80% fast-moving heparin and 20% dermatan sulfate, that exhibits anti-thrombotic and profibrinolytic properties and may inhibit endothelial glycocalyx breakdown 63, 64 . However, although sulodexide reduced urine albumin excretion in patients with type 2 diabetic nephropathy, it failed to show benefit in a multicentre placebo-controlled double-blinded Phase III study 65 . Although other approaches to restore the endothelial glycocalyx, such as the use of chemical heparanase inhibition, are being investigated, they have not yet been put into clinical development 66 .
Endothelin receptor antagonists.
Preclinical studies of animal models with kidney disease have suggested that selective blockade of the endothelin A receptor (ET A receptor) is associated with renal protection when used in addition to existing therapies, such as RAS interventions 67 (FIG. 2) . Several potential mechanisms for ET A receptor blockade providing renal protection have been proposed. First, ET A receptor blockade has vascular effects, which cause glomerular vasodilation 68 , and the ET A receptor antagonist atrasentan has been shown to reduce albuminuria 69 (TABLE 1) . Second, endothelin has been associated with renal inflammation, which is reduced by ET A receptor blockade, perhaps by mitigating the inflammatory effects of albuminuria [70] [71] [72] . Last, endothelin has been implicated in the deposition of collagen and fibrosis, and thus ET A receptor antagonists may directly reduce fibrosis in the kidney [72] [73] [74] . However, a renal outcomes study using the ET A receptor antagonist avosentan was prematurely terminated because of a threefold increase in fluid retention and heart failure compared with placebo 75 ; therefore, it was not determined whether avosentan slowed the progression of eGFR decline. It has been hypothesized that fluid retention is driven by the ET B receptor-blocking capacity of the drugs, although there are also reports of sodium retention induced by ET A receptor blockade 69, 76 . Based on this hypothesis, a hard renal outcome trial (SONAR) using the more selective ET A receptor antagonist atrasentan has been initiated ( Table 1) . In this trial, 4,100 patients will be treated for 48 months with a primary outcome of creatinine doubling, ESRD or death.
Because of the previous association of these drugs with congestive heart failure, the trial will specifically exclude patients with a previous history of congestive heart failure, pedal oedema or with a current B-type natriuretic peptide (BNP) level of >200 pg per ml. The anticipated completion date of this trial is in 2017 (REF. 77 ).
Anti-inflammatory therapy
An association between inflammation and diabetic renal failure has long been recognized 17, 78 (FIG. 3) . Bohle et al. 79 described the association of increased tubulo interstitial inflammatory cell infiltrate in diabetic nephropathy human kidney biopsies with higher serum creatinine levels and longer duration of disease. More recent mRNA profiling of renal biopsies from patients with diabetic nephropathy confirmed that inflammatory pathways are significantly increased in glomeruli and tubules 17, 78 . These studies provided evidence for stimulation of macrophage and dendritic cell maturation pathways and cytotoxic T lymphocyte-mediated apoptosis, in glomeruli as well as in the tubulointerstitial compartments. In later stages of kidney disease, leukocyte migration and complement system signatures were identified in glomeruli 17 . However, even patients with early stages of disease had evidence of activation of inflammatory pathways, including the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and nuclear factor-κB (NF-κB) pathways 78, 80 .
Tumour necrosis factor inhibition. The findings above are congruent with earlier studies suggesting that, in diabetes, hyperglycaemia-associated advanced glycosylation end-products activate tumour necrosis factor (TNF) production by macrophages 81 (FIG. 3) . Increased macrophage TNF and interleukin-1 (IL-1) production were shown to be induced by glomerular basement membrane from streptozotocin-treated rats compared with controls 82 . These findings are of particular note, as it has recently been demonstrated that circulating levels of soluble TNF receptor 1 (sTNFR1) and sTNFR2 predict a higher rate of progression to ESRD over the following decade in patients with either type 1 or type 2 diabetes and nephropathy 83, 84 . Membrane-associated TNFR1 and TNFR2 have important roles in activating chemokine and cytokine release 85 . Interestingly, baseline circulating TNF levels were only moderately increased in patients who later developed ESRD, consistent with the possibility that membrane-associated TNF as opposed to circulating TNF could serve as the activating ligand 86, 87 . It is notable that levels of both forms of the circulating sTNFR are increased and predictive of progression [88] [89] [90] , as TNFR1 and TNFR2 have been associated with different functions. TNFR2 appears to be selectively expressed in endothelium and leukocytes, whereas TNFR1 is widely expressed 88, 90 . In addition, TNFR1 and TNFR2 can be associated with different functions. A renal protective role for TNFR1 has also been postulated as deletion of this receptor is associated with higher systolic pressure and urinary albumin excretion, as well as an altered GFR 91, 92 . TNFR2 has been shown to exert positive inotropic effects in cardiac myocytes through enhanced calcium handling 93 . Whether TNF or its receptors have pathogenic roles in CKD progression or diabetic nephropathy remains uncertain. In preclinical rodent models of kidney disease, TNFR-deficient animals or mice treated with TNFneutralizing antibodies have reduced disease severity 91, 94 . Nevertheless, despite anti-TNF agents having been used clinically for more than two decades, there have been few studies examining their clinical activity in kidney disease. Any such studies that were performed were relatively small and mainly focused on lupus nephritis and focal segmental glomerulosclerosis (FSGS), leaving their potential activity in other forms of CKD progression unaddressed 88, 91 . CC-chemokine receptor 2 inhibition. CC-chemokine ligand 2 (CCL2; also known as MCP1) is a secreted protein that is 99 amino acids in length and that interacts with the CC-chemokine receptor 2 (CCR2) on T cells and macrophages, recruiting these cells to sites of tissue injury 95, 96 (FIG. 3) . Renal expression of CCL2 is increased in patients with proteinuric diabetic nephropathy, and this cytokine is predominantly expressed in the tubulointerstitium rather than the glomerulus [97] [98] [99] . Urinary excretion of CCL2 is also increased in patients with diabetic nephropathy, and higher urine levels of CCL2 seem to be predictive of worse renal outcomes 100 . Similarly, in animal models, blockade of CCR2 ameliorated progression of diabetic nephropathy in db/db mice as well as in diabetic Ins2 C96Y Akita mice 101, 102 . Several companies have established clinical programmes to test the efficacy of CCR2 inhibitors in human diabetic nephropathy. ChemoCentryx and Pfizer have ongoing clinical development programmes of oral receptor antagonists for CCL2-CCR2 (CCX140; ChemoCentryx) and CCR2-CCR5 (PF-04634817; Pfizer), and these antagonists are being tested for their ability to reduce proteinuria in patients with diabetic nephropathy 103,104 (TABLE 1) .
A 52-week Phase II clinical trial of CCX140 in 332 patients with diabetic nephropathy 105, 106 met its primary end point, demonstrating that treatment with a combination of CCX140 and an ACEI or an ARB significantly reduced the UACR beyond that achieved with standard of care. The maximum treatment effect, an 18% reduction in UACR, was seen in the 5 mg dose group at 12 weeks, and sustained reduction in albuminuria induced by CCX140 relative to standard of care alone was observed over the full year 105 . Whether the reported reduction in albuminuria will translate into long-term improvements in patient outcomes and reduce the rate of renal function deterioration remains to be tested. At the time of writing this Review, results from Pfizer's Phase II trial of PF-04634817 were not publically available.
JAK-STAT inhibition. JAK and STAT are important intracellular mediators of receptors for erythropoie tin, growth hormone and pro-epidermal growth factor (EGF), as well as inflammatory signalling interferons IL-6, IL-12, IL-23 and interferon-α (IFNα) 107, 108 (FIG. 3) . Binding of such ligands to their receptors leads to multimer or homodimer assembly, activating the auto-phosphorylation activity of JAK and the subsequent phosphorylation of STAT and its translocation to the nucleus 109 . This translocation results in the transcription of additional pro-inflammatory target genes, including CCL2, as well as GATA3, IL24 and suppressor of cytokine signalling 1 (SOCS1) [110] [111] [112] [113] . Increased expression of these genes comprises a major genetic signature in diabetic nephropathy and lupus nephritis 78, 80, 114, 115 . Evidence of JAK-STAT activation in experimental models of kidney disease, including diabetic mice and rats, has also been observed 17, 78, 80 , and the use of a non-selective JAK inhibitor (AG490) significantly reduced urinary protein excretion in diabetic rats 116 . Recently, JAK inhibitors including tofacitinib and baricitinib have been tested in the clinic and found to be efficacious in autoimmune inflammatory diseases, including rheumatoid arthritis and ulcerative colitis 112, 115, [117] [118] [119] . The documented clinical anti-inflammatory efficacy of JAK inhibitors, together with the gene pathway signature in diabetic nephropathy, has prompted a Phase II exploration to test the clinical efficacy of these JAK inhibitors in kidney disease 95, 120 . The effects of 24-week treatment with the JAK1 and JAK2 inhibitor baricitinib on albuminuria has been investigated in 129 patients with proteinuric diabetic nephropathy already taking an ACEI or an ARB 120 . Baricitinib treatment was associated with a 30-40% dose-dependent reduction in albuminuria. However, reduced haemoglobin was observed, a side effect that is associated with this class of drugs 120 . It will be necessary to determine whether these effects on albuminuria reduction translate into long-term benefit on kidney function and mortality.
Complement inhibition.
Complement activation has a well-established role in the pathogenesis of diverse renal disease, including membranoproliferative glomerulonephritis (MPGN), post-infectious glomerulonephritis, haemolytic uraemic syndrome and IgA nephropathy 106, 121 . Eculizumab (Alexion Pharmaceuticals) is a monoclonal antibody to complement protein C5 that blocks the cleavage of C5 to C5a and C5b, thereby preventing the generation of the pro-inflammatory peptide C5a and the membrane-attack complex C5b-9 (REF. 122) (FIG. 3) . Eculizumab treatment improved the eGFR in patients with atypical haemolytic uraemic syndrome and associated thrombotic microangio pathy 122, 123 . Although these were small Phase II trials, the effects were sufficiently profound to support registration of eculizumab as a therapy for this disorder, for which it is now approved.
In addition to immune glomerulonephritides, complement activation has been proposed to contribute to the pathogenesis of diabetic nephropathy, possibly through glucose-associated production of neoepitopes activating the lectin-complement pathway 124, 125 . This hypothesis has received additional support from molecular profiling studies of human diabetic nephropathy kidney biopsies and plasma, which show complement to be among the most activated pathways 17, 126 . C3 is robustly expressed in kidney biopsies from patients with diabetic nephropathy 17 . Although complement inhibition has not been clinically tested in diabetic nephropathy, inhibition of complement in animal models of the disease supports its potential therapeutic benefit 127 . However, the potential risk of increased infections with this approach must be considered 123 .
Apoptosis signalling kinase 1 inhibition. Apoptosis signalling kinase 1 (ASK1, also known as MAP3K5) is a stress-responsive kinase that can be activated by multiple stimuli, including reactive oxygen species (ROS) and TNF activation of TNFR1 (REFS 128, 129) . ASK1 signals . Several potential therapeutic strategies are shown including: blocking increased transforming growth factor-β (TGFβ) signalling with the neutralizing antibody CAT-192; blocking latent TGFβ by inhibiting αvβ6 integrin with STX-100 antibody; preventing tubule dedifferentiation and induction of a proinflammatory phenotype (which is due to increased Janus kinase (JAK) and Notch signalling) with the γ-secretase inhibitor (GSI) or baricitinib; preventing increased tumour necrosis factor (TNF) and CC-chemokine ligand 2 (CCL2) levels, inhibiting complement activation using eculizumab; preventing collagen crosslinking by LOXL2 using simtuzumab; and blocking increased GLI2 and WNT signalling in fibroblasts to prevent activated myofibroblast accumulation. Part c shows a PAS-stained human kidney section from a patient with diabetic kidney disease. Note the increased interstitial matrix, the increase in myofibroblasts and inflammatory cells and tubule cell dedifferentiation. BIO, 6-bromoindirubin-3ʹ-oxime; HH, hedgehog.
through a cascade of downstream kinases, including p38 and JUN N-terminal kinase (JNK), which leads to the expression of target genes, including those encoding inflammatory cytokines 130, 131 . A preliminary report suggests that ASK1 inhibition substantially improves glomerulosclerosis in a diabetic animal model 132 . Gilead Sciences has initiated a 300-patient Phase II programme to test the efficacy of the selective ASK1 inhibitor GS-4997 in diabetic nephropathy. The primary outcome is the change in eGFR following 48 weeks of treatment. A secon dary outcome will determine the proportion of participants achieving at least a 30% reduction in albuminuria from baseline at week 48 (REF. 133, 134) .
Vascular adhesion protein 1 inhibition. Accumulating evidence pointing to renal inflammation in the pathogenesis of progressive kidney disease 135 has generated interest in strategies to impede trans-capillary migration of inflammatory cells into the diseased kidney. Vascular adhesion protein 1 (VAP1, also known as AOC3) is an endothelial sialoglycoprotein, the cell surface expression of which is induced under inflammatory conditions 136, 137 . VAP1, possesses monoamine oxidase activity and also interacts with leukocyte adhesion molecules including sialic acid-binding Ig-like lectin 9 (Siglec-9) and Siglec-10 (REF. 138 ). Both of these functions are important in facilitating leukocyte egress into inflamed tissue 136 . Based on these findings, Astellas has initiated a Phase II study of ASP8232 -a small-molecule inhibitor of VAP1 activity, in 110 patients with diabetic nephropathy 139 . The trial will investigate UACR reduction following 12 weeks of treatment and is anticipated to read out in June 2016 (TABLE 1) .
Targeting fibrosis
Tubulointerstitial fibrosis is the common histological manifestation of CKD, almost regardless of disease aetiology (FIG. 3) . The degree of fibrosis is a strong predictor of future GFR decline and often an important reason why biopsies are performed 79 . Tubulointerstitial fibrosis shows similarities to other fibrotic conditions, including lung fibrosis and liver cirrhosis 140 . Common mechanisms identified in fibrosis include: epithelial injury, fibroblast activation, matrix deposition and inflammation, all of which provide potential therapeutic targets 141 .
Transforming growth factor-β inhibition. Cell culture and mouse model data strongly support transforming growth factor-β1 (TGFβ1) as the key driver of the accumulation of collagen and activated myofibroblasts, which is characteristic of fibrosis 142 . Inhibiting TGFβ1 signalling therefore represents a promising antifibrotic therapeutic approach (FIG. 3) . However, clinical trials with CAT-192 (developed by Genzyme), a recombinant human antibody that neutralizes TGFβ1 in the treatment of early-stage diffuse cutaneous systemic sclerosis, failed to show benefit in diabetic kidney disease (FIG. 3) . Similarly, Phase II trials with a TGFβ1-neutralizing antibody (namely LY2382770, developed by Lilly) did not show clinically significant improvement in patients with diabetic kidney disease 143 . Systemic toxicity associated with the inhibition of TGFβ1 may limit the maximal tolerated dose of anti-TGFβ1 therapies 144 . Further studies are needed to understand the complex role of TGFβ1 in fibrosis and identify approaches that would avoid systemic inhibition.
One such approach that has recently emerged involves targeting the αvβ6 integrin. αvβ6 integrin is an epithelial-specific integrin that binds to and activates latent TGFβ1 (REF. 145 ). An anti-αvβ6 neutralizing antibody developed by Biogen (STX100) has shown benefit in multiple fibrosis models 145, 146 and is currently undergoing Phase II trials in idiopathic pulmonary fibrosis (IPF) (FIG. 3) .
Pirfenidone. Pirfenidone has recently been approved for the treatment of IPF as it has shown significant benefit in reducing pulmonary function decline in Phase III trials 147 . The mechanism of action of pirfenidone is not fully understood; in cell culture studies it suppresses collagen expression and has an anti-inflammatory effect 148, 149 . Pirfenidone showed modest clinical benefit in a randomized, double-blinded, placebo-controlled Phase II study in 77 patients with diabetic nephro pathy who had elevated albuminuria and reduced eGFR. Among the 52 patients whom completed the study, a significant increase in the mean eGFR was reported in the pirfenidone group compared with the placebo group 150 . Galectin 3 inhibition. Galectin 3 is a member of the lectin family with antimicrobial activity against bacteria and fungi. It has been shown to be involved in an array of biological processes, including cell adhesion, growth, differentiation, fibrosis, heart disease, cancer and stroke 151 (FIG. 3) . Human studies indicate a correlation between galectin 3 levels and ESRD, pulmonary fibrosis, heart disease and cancer 152 . Galecto Biotech is currently developing galectin 3 inhibitors for the treatment of fibrosis, specifically IPF 153 . It will be interesting to also investigate the effects of galectin 3 inhibitors on kidney disease progression.
Lysophosphatidic acid receptor antagonists. Fibrosis is associated with increased lysophosphatidic acid (LPA) production as well as increased expression of its receptors (mainly LPA receptor 1 (LPAR1)) in a number of organs 154 (FIG. 3) . LPA is a bioactive mediator that acts through specific G protein-coupled receptors 155 . The contribution of the LPAR1 subtype to the development of kidney, lung, vascular and dermal fibrosis was dem onstrated using genetic (knockout mice) and pharmacological approaches 156 . To date, LPAR1 antagonists have passed Phase I and Phase II clinical trials for IPF and systemic sclerosis 157 , and they may be tested in kidney disease in the future.
Tranilast. Tranilast (Kissei Pharmaceutical) has been marketed in Japan since 1982 for the treatment of allergic diseases and more recently for the treatment of keloid scars and hypertrophic scars 158, 159 (FIG. 3) . In pilot studies, a tranilast derivative, 3-methoxy-4-propargyloxycinnamoyl anthranilate (also known as FT011, Fibrotech Therapeutics), was shown to reduce albuminuria in a rat model of diabetic nephropathy 160 . In cell culture studies, FT011 inhibits both TGFβ-and PDGF-induced collagen production 161 . At present, we are not aware of an active development programme for either tranilast or FT011 in diabetic kidney disease.
Lysyl oxidase inhibition.
Lysyl oxidase is an extracellular copper-dependent amine oxidase that catalyses the first step in the formation of crosslinks in collagens and elastin 162, 163 . Collagen crosslinking is crucial for fibrosis development (FIG. 3) . Gilead Sciences have developed a new humanized monoclonal antibody (simtuzumab) that binds to and inhibits lysyl oxidase homologue 2 (LOXL2) and that is currently in clinical trials for lung and liver fibrosis. Based on its mechanism of action, simtuzumab may also show benefit in kidney fibrosis 164 .
Targeting microRNAs. Mouse models of IPF have indicated decreased expression of microRNA 29 (miR-29) in bleomycin-induced fibrosis 165 . Additional studies have indicated that miR-29 is an important regulator of TGFβ expression 165 , and miRagen Therapeutics have developed miR-29 mimics that are now being tested for the treatment of IPF. Notably, miR-29 has shown similar expression patterns in mouse models of kidney fibrosis 166 , indicating that this miRNA could be a potential therapeutic target. Another miRNA, miR-21, might also represent an important target in the kidney 167 (see below).
Developmental pathways.
Unbiased transcriptome analysis studies have highlighted the reactivation of multiple developmental pathways including WNT-Notch and Hedgehog pathways (which have crucial roles in kidney development) in patient samples and animal models of CKD 14, 17, 168, 169 (FIG. 3) . Although transient activation of any of these pathways is likely to be important in regeneration and repair after an acute injury, sustained activation of these pathways has been shown to induce fibrosis development in mouse models 170 . Increased chronic expression of Notch in tubule epithelial cells induced fibrosis development in mouse models, whereas genetic deletion of the Notch pathway from tubule cells or pharmacological inhibition of Notch activation ameliorated kidney disease development 14 . Notch seems to play an important part in mediating epithelial dedifferentiation, which is a key aspect of fibrosis. On the contrary, the GLI-Hedgehog pathway seems to play an important part in myofibroblast proliferation and transdifferentiation 169 . Genetic or pharmacological inhibition of Hedgehog signalling in fibroblasts was able to not only halt, but also reverse fibrosis in a mouse model 14, 169, 171 . Therefore, although these pathways may represent new and potentially attractive therapeutic targets, at present, further studies are needed to better differentiate their profibrotic and regenerative activities.
Metabolic dysregulation in diabetes and CKD
Metabolic dysregulation, particularly poor glucose control, is associated with an increased rate of development of complications such as kidney disease in patients with type 1 and type 2 diabetes 172, 173 . Indeed, cells incubated in high glucose concentrations or increased fatty acid levels show significant changes in their metabolic profiles 174 . Increased generation of ROS from mitochondrial oxidase or plasma membrane oxidase has been proposed to be the unifying theme leading to cell damage 175 (FIG. 4) .
However, recent studies exploring the effects of glucose normalization on diabetic kidney disease have presented unexpected observations. Findings from the Diabetes Complication Cohort Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) indicate that patients with initial poor glycaemic control continue to develop a higher rate of kidney and cardiovascular disease despite several decades of improved glycaemia 172 . Furthermore, we have also learned that, in most patients with type 2 diabetes and existing kidney disease, targeting a glycated haemoglobin level below 6.0% -almost to the degree of 'normalization' of glucose levels -does not translate into reduced development of complications 176, 177 . The term 'metabolic memory' has been proposed to explain these results, indicating that cells are reprogrammed by prior episodes of metabolic derangements and continue to respond differently 178 . Epigenetic changes might provide the mechanistic basis for this metabolic memory effect 179 . Epigenetic enzymes require substrates of intermediate metabolism such as methyl and acetyl groups, which is the likely molecular mechanism by which environmental changes and nutrient availability can have a long-term influence on cellular behaviour even after the insult is removed 180 . Animal model studies and some human observations have indicated epigenetic differences in patients with diabetic kidney disease and CKD 178, 181 . Therefore, targeting metabolism represents a promising therapeutic strategy for multiple reasons: metabolic dysregulation is one of the most proximal mechanisms in diabetes and is known to play a part in kidney disease development; acute metabolic derangements probably have a long-term impact on the development of complications by epigenetic reprogramming; and, at later stages, insufficient energy availability is an important mechanism contributing to CKD development 179, 182 . Sodium-glucose co-transporter 2 inhibition. The sodiumglucose co-transporter 2 (SGLT2) is the major renal glucose re-uptake mechanism in the apical membrane of the proximal tubule 183 (FIG. 4) . SGLT2 inhibitors have entered clinical practice as glucose control agents for people with diabetes through their ability to inhibit renal glucose absorption and reduce hyperglycaemia 184, 185 . Studies in type 1 and type 2 diabetic mice show that SGLT2 inhibition not only reduces hyperglycaemia but also has beneficial effects in diabetic kidney disease, including reduced glomerular hyperfiltration, renal hypertrophy and albuminuria, as well as decreased systolic blood pressure 186, 187 . These findings were interpreted as being consistent with a crucial role for the suppression of tubuloglomerular feedback in hyperfiltration in diabetes. By blocking glucose-coupled sodium reabsorption, SGLT2 inhibition is thought to increase sodium delivery to the macula densa, activating constrictor signals to the afferent arteriole and thereby reducing glomerular filtration pressure 188 . Therefore, the proposed effect of SGLT2 inhibitors to reduce glomerular filtration pressure overlaps with the mechanisms attributed to ACEI-ARB therapy, although SGLT2 inhibition may target the afferent arteriole more selectively. Similar to ACEI-ARB treatment, a Phase II trial of the SGLT2 inhibitor canagliflozin in people with type 2 diabetics and CKD revealed an acute reduction in eGFR followed by eGFR stabilization 184 . This effect was accompanied by a significant and dose-dependent reduction in albuminuria. To determine whether the observed decrease in albuminuria translates to improved outcomes in patients with diabetic nephropathy, Janssen has initiated a Phase III study of canagliflozin. The CREDENCE trial will enrol 3,700 patients at 531 sites globally 189 . The primary composite end point of the study includes ESRD, doubling of serum creatinine, and renal or cardiovascular death. Results from this trial are expected in early 2020 (TABLE 1) .
Lipid metabolism. Renal tubular and glomerular epi thelial cells require high energy levels and are densely packed with mitochondria. Their primary source of energy comes from fatty acid oxidation. Genetic mutations in mitochondrial enzymes have been shown to result in severe tubulointerstitial fibrosis and glomerulosclerosis 190, 191 (FIG. 4) . As non-transformed cells do not use glucose in high amounts, decreased fatty acid oxidation induces accelerated cell death and dedifferentiation of the cells 182 . Nuclear receptors, including peroxisome proliferatoractivated receptor-α (PPARα), PPARγ co-activator 1α (PGC1α, also known as PPARGC1A) and liver X receptor (LXR) pathways have been shown to be key regulators of fatty acid metabolism in tubule cells 192 . Indeed, transgenic expression of PPARα was able to ameliorate CKD development in animal models 193 . Pharmacological activators of PPARα (mostly fibrates) have been in clinical use for treatment of serum lipid abnormalities for many years. Metabolic dysregulation, particularly poor glucose control, is associated with the development of diabetic nephropathy. Key factors contributing to disease development include increased sodiumglucose co-transporter 2 (SGLT2)-mediated glucose uptake and increased mitochondrial and plasma membrane reactive oxygen species (ROS) generation. In addition, fatty acid oxidation is decreased owing to loss of nuclear receptor activity of peroxisome proliferator-activated receptor-α (PPARα), retinoid X receptor (RXR), PPARγ co-activator 1α (PGC1α), liver X receptor-farnesoid X receptor (LXR-FXR) as well as their upstream regulator 5′-AMP-activated protein kinase (AMPK)), liver kinase B1 (LKB1) and microRNA 21 (miR-21). Effects of metabolic fluctuations are long lasting as they can influence the epigenome (through cytosine methylation and histone acetylation). Agents being investigated that target many of these alterations are shown in red and blue boxes and include: empagliflozin, dapagliflozin and canagliflozin (which block SGLT2), GTK137831 (which blocks NADPH oxidase 4 (NOX4)), azacitidine (which blocks cytosine methylation), miR-21 and fibrates (which activate PPARα), GW3965 (which blocks LXR-FXR) and histone deacetylase (HDAC) inhibitors. AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside.
Two clinical trials -FIELD and ACCORD -have examined the effectiveness of fibrates on kidney disease development, and both trials reported a significant reduction in albuminuria development in diabetic patients 194, 195 (FIG. 4) . Unfortunately, fibrates raise serum creatinine levels, possibly by interfering with creatinine secretion, and therefore determining their effectiveness in GFR decline cannot be directly studied using serum creatinine levels. The follow-up wash-out study indicates that the GFR decline was statistically slower in the fibrate-treated group compared with controls 196, 197 . Upstream targeting of the pathway at the level of 5ʹ-AMP-activated protein kinase (AMPK) or liver kinase B1 (LKB1, also known as STK11), which is an important regulator of AMPK and downstream metabolism, might also offer therapeutic benefits 198 (FIG. 4) . The AMPK agonist, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), has shown significant benefit in mouse models of diabetic kidney disease and other forms of CKD 199 . miR-21 antagonism. miR-21 was one of the first miRNAs to be discovered, is fairly abundant, and, similar to many other mi RNAs, it has pleotropic functions associated with phosphatase and tensin homologue (PTEN), TGFβ and tumour suppression 200 . Mouse model studies have reported a protective role for miR-21 antagonism in heart fibrosis development 201, 202 (FIG. 4) . Moreover, small molecule antagonism of miR-21 (REF. 203 ) has shown a marked protective effect in several mouse fibrosis models 167 . miR-21 in the kidney affects multiple metabolic pathways converging on PPARA and ultimately improving mitochondrial function and metabolism 203 . However, it is interesting to note that genetic deletion of miR-21 does not seem to recapitulate the effect of pharmacological inhibition 204 . Further studies are therefore needed to determine whether miR-21 could potentially be modulated in the treatment of kidney disease.
NADPH oxidase inhibition.
Increased generation of ROS from mitochondrial sources has been proposed as a unifying hypothesis for the development of diabetic complications 205 . Both mitochondrial and plasma membrane NADPH oxidases contribute to increases in ROS levels in diabetes 174 . In addition, inhibition of the plasma membrane-specific NADPH oxidase has shown significant benefit in different rodent models of fibrosis 174 . The kidney-specific NADPH oxidase isoform NOX4 has recently received substantial attention, as specific NOX4 inhibitors seem to show benefit in mouse models of diabetic kidney disease 206 (FIG. 4) . NOX4 inhibitors seem to be broadly effective in fibrosis, as recent studies have also indicated beneficial effects in models of pulmonary and liver fibrosis [207] [208] [209] . In 2012, Genkyotex announced the successful completion of a Phase Ia study with GKT137831, a first-in-class inhibitor targeting NOX1 and NOX4 (REF. 206) (TABLE 1) . GKT137831 seems to be safe and well tolerated following oral administration. Phase II studies for diabetic kidney disease with GTK137831 have been completed, but results remain to be reported. Pyridorin (pyridoxamine dihydrochloride, under development by NephroGenex) is a novel compound that is a derivative of vitamin B6, shown to target and reduce pathogenic oxidative chemistries 210 . However, a Phase II efficacy study failed to show a robust effect in patients with diabetic nephropathy 211 . A Phase III trial (the PIONEER trial) of pyridorin in patients with earlier-stage diabetic nephropathy is ongoing (TABLE 1) .
Epigenetic targets -histone deacetylase and cytosine methylation. The effect of acute metabolic changes often may not be detected until later stages of disease as they can result in long-term epigenetic modifications (FIG. 4) . Several studies have reported differences in cytosine methylation levels between control and human kidney disease samples 212 . Increased methylation of the RASAL1 gene, which encodes an inhibitor of the RAS oncoprotein, has been associated with fibroblast activation and fibrogenesis in the kidney 212 . RASAL1 hypermethylation is mediated by the methyltransferase DNMT1, and in mouse models of kidney fibrosis, genetic deletion of Dnmt1 or pharmacological inhibition of the enzyme protected animals from kidney fibrosis development 212 . Studies from our laboratory have also shown that methylation differences target key profibrotic pathways, indicating that they are functionally important 181 . Histone modifications represent another important epigenetic regulator of gene transcription. Inhibitors of histone deacetylases (HDACs) have been reproducibly shown to ameliorate fibrosis development in different models 213, 214 (FIG. 4) . However, as these drugs broadly interfere with transcription, extended safety studies are needed to understand their side-effect profiles.
Targeting podocytes and albuminuria
The presence of albuminuria in a patient with diabetes and CKD currently fulfils the diagnostic criteria for diabetic CKD (FIG. 2) . Albuminuria, used in conjunction with gender, GFR and serum phosphorus level, is an excellent predictor of future glomerular function decline; therefore, most Phase II studies use albuminuria as an intermediate outcome 7 . Human genetic studies of patients with rare monogenic diseases -FSGS and minimal change disease 191 -indicate that podocytes play a crucial part in albuminuria and glomerulosclerosis, as almost all monogenic mutations are podocyte specific proteins 191 . Mouse genetic models have further substantiated the role of podocytes in proteinuria 168, 215 . Furthermore, podocytes are unable to divide and they have limited (if any) capacity to be replaced 216 . The slit diaphragm (which is a junction between podocyte foot processes), the glomerular basement membrane and the fenestrated endothelial cells represent the key barriers to albumin leakage into the urine 216 (FIG. 2) . Over the years, we have learned that the slit diaphragm acts as a signalling platform 217 . Proteinuric disease conditions are almost uniformly associated with foot process simplification of podocytes, which is caused by reorganization of the actin cytoskeleton 191 . These changes are identified as foot process effacement by histopathological examination. Nephrin clustering and endocytosis are associated with changes in the actin cytoskeleton, cell adhesion and endocytosis [218] [219] [220] , and have a key role in proteinuria development. Although proteinuria and foot process effacement are reversible conditions, the critical point of no return is reached upon 20% podocyte loss, owing to apoptosis, detachment or dedifferentiation 221, 222 . At this point, glomerulosclerosis develops, leading to a decrease in GFR.
Abatacept. CD80 (also known as B7) is a membrane protein found on activated antigen-presenting cells that can produce a co-stimulatory signal to enhance the activity of T cells 223 . Interestingly, CD80 expression is increased in podocytes in a subset of patients with FSGS 224 (FIG. 2) .
Abatacept is a clinically approved inhibitor of CD80 signalling for the treatment of rheumatoid arthritis, and this inhibitor acts by blocking the interaction between CD80 and its receptors 225 . Abatacept treatment of five patients with CD80
+ FSGS resulted in a significant reduction of proteinuria, but these results were not replicated in other cohorts 226 . Mouse model studies indicate that a similar mechanism might be present in models of diabetic kidney disease 227 . Larger clinical studies are needed to determine the clinical benefit of abatacept in these disease conditions, which are currently hindered by difficulties of reliable detection of CD80 expression in kidney tissue samples 226 .
Targeting the actin cytoskeleton. Recent reports indicate that Bis-T-23, a compound that promotes actindependent dynamin oligomerization and thus increases actin polymerization in injured podocytes, improves renal health both in transient kidney disease and in CKD models 228 (FIG. 2) . Bis-T-23 has been reported to interact with the GTPase dynamin 219 , which has been implicated in the maintenance of cellular architecture in podocytes through its direct interaction with actin. Dynamin oligomerization seems to have an important role in actin polymerization and global organization of the actin cytoskeleton in the cell 228 . Further studies into the therapeutic potential of promoting dynamin oligomerization for the treatment of kidney disease are therefore warranted.
Integrin inhibition. VPI-2690B (Vascular Pharmaceuticals) is a monoclonal antibody that binds to the C-loop domain sequence of αvβ3 integrin (REF. 229 ). This antibody has been shown to reduce albuminuria in diabetic rats and atherosclerosis in diabetic pigs 230, 231 . It has been proposed that these effects are mediated by blocking the action of αvβ3 integrin to stimulate insulin-like growth factor 1 (IGF1) signalling in vascular smooth muscle cells and mesangial cells [229] [230] [231] . αvβ3 integrin might also play a part in podocyte and matrix interaction. VPI-2690B is currently in Phase II clinical testing for the treatment of diabetic nephropathy 232 . This placebo-controlled trial will enrol 300 patients with diabetes and is projected to complete in August 2017 (TABLE 1) .
Additional agents in development
There are several other agents, which do not fall into the classes discussed above, that are also being clinically investigated for the treatment of CKD.
Phosphodiesterase inhibitors. Pentoxifylline, a methylxanthine derivative and nonspecific phosphodiesterase inhibitor, has long been proposed as a therapy for diabetic nephropathy 233 .
The recently completed PREDIAN study tested the effects of 24 months of pentoxifylline treatment on proteinuria and eGFR decline in 160 patients with type 2 diabetes and nephropathy 234 . Patients that received pentoxifylline experienced a marked reduction in albuminuria, but there was only a relatively small effect on eGFR. Similarly, in a preliminary report, Pfizer carried out a Phase II trial of the phosphodiesterase 4 (PDE4) and PDE5 inhibitor PF-04634817 in 256 patients with diabetic nephropathy 235 . Following 12 weeks of treatment, the UACR was significantly reduced in pentoxifyllinetreated patients compared with patients who received placebo. In addition, Phase II testing of phosphodiesterase inhibition with CTP-499, a deuterated analogue of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine (an active metabolite of pentoxifylline), in patients with type 2 diabetes mellitus and nephropathy has been undertaken by Concert Pharmaceuticals (TABLE 1) . Although this trial has been completed, the full results have not yet been reported. Thus, although phosphodiesterase inhibition appears to have beneficial effects on albuminuria in ACEI-or ARB-treated patients, it remains to be determined whether these observations will translate into a benefit in renal outcomes and a reduction in the requirement for dialysis.
Allopurinol.
Clinical observational studies indicate a strong correlation between serum uric acid levels and the loss of kidney function in diabetic patients 236 . However, whether high uric acid levels actually cause renal function decline remains unclear. Two small clinical trials have provided proof of concept for using allopurinol to lower the risk of kidney function decline. One of the studies included only 51 patients with high serum urate levels, and although the other study had more than 100 participants, the average age in that cohort was unusually high [237] [238] [239] . It is therefore not yet clear whether these results can be generalized to all patients with diabetic kidney disease. A large US National Institutes of Health (NIH)-funded clinical trial -the Preventing Early Renal function Loss (PERL) study -has been formed to test this hypothesis 240 . The PERL study specifically targets patients with type 1 diabetes and relatively preserved kidney function who are at high risk for progression (TABLE 1) .
Sodium bicarbonate. One key function of the kidney is to excrete acids that are generated from the metabolism of proteins. In the urine, most proteins are excreted as ammonia. Ammoniagenesis is decreased in the early stages of CKD, and many patients with CKD develop metabolic acidosis 26 . As most enzymes operate within a narrow pH range, even small changes in pH could have a substantial effect on their activity. Metabolic acidosis can activate the complement pathway, leading to low-grade persistent complement activation and inflammation 241 . Small clinical trials aiming to correct acidosis have indicated a benefit of treating patients with sodium bicarbonate 242 . Larger double-blinded placebo-controlled trials are currently being conducted to determine whether sodium bicarbonate treatment may slow the progression of renal disease.
Hurdles to developing new CKD therapies
There are a number of challenges facing the development of new treatments for CKD. In particular, several factors must be considered in the design of future clinical trials, including issues regarding patient recruitment and selection, as well as the identification of appropriate end points and efficacy biomarkers. It must be noted that testing of novel therapies aimed at slowing progression of proteinuric CKD must be performed in patients already receiving the standard of care, namely ACEI and ARB therapy.
Disease awareness and clinical trial recruitment. The number of randomized controlled trials in nephrology is lower than that for almost any other medical subspecialty 243 . The specific factors contributing to this gap are complex, but they certainly 7, 9 include lack of patient disease awareness and self-advocacy 244 . Research has shown that disease awareness in patients with CKD stages 1-3 is as low as 5%, even in patients that have seen a physician within the last year [244] [245] [246] [247] . A physician may neglect to inform their patient that they have kidney disease, perhaps in part because the physician does not believe that they can offer effective therapeutic options.
These issues undoubtedly contribute to major operational difficulties in executing trials designed to slow the progression of kidney disease to dialysis -especially low recruitment rates 248, 249 . Overall recruitment rates for diabetic kidney disease trials are approximately 0.20 patients per site per month, which is about a quarter of the number of patients enrolled per month for a diabetes trial. Although the size of clinical trials may be similar to diabetes mellitus studies, the rate at which patients enrol into diabetic kidney disease trials substantially delays timelines, increases costs and negatively impacts the willingness of major pharmaceutical companies to invest in these trials. Clinical trial networks and patient registries can facilitate patient identification and improve the recruitment rate in clinical trials for testing therapies. Although clinical trial networks for acute kidney injury have been established, CKD trial networks that include the two major causes of CKD (diabetic nephropathy and hypertension) are just now being initiated in Canada and Italy, but these networks do not include the United States, the rest of Europe or Asia 245, 250 .
Patient selection. Pre-screening of patients and clear inclusion and exclusion criteria should balance the desire to eliminate likely biological non-responders who decrease trial efficiency with the need to rapidly accrue patients who are representative of the disease population. These design choices require a sophisticated Kidney function decline in patients follows a highly heterogeneous pattern. Recent results of the large Chronic Renal Insufficiency Cohort (CRIC) indicate that the mean decline in the glomerular filtration rate (GFR) of patients with stage 3 diabetic chronic kidney disease (CKD) is around 1.5-3 ml per year 265 . However, a subset of patients follows a more rapid kidney function decline, and these patients can be considered 'rapid progressors'. Unfortunately, at present, there is no consensus definition for rapid progression. Expert consensus suggested the use of a decline of >5 ml per min per 1.73m 2 per year 266 . Results from the CRIC cohort indicate that a decline of >3 ml per min per 1.73m 2 is already 2 standard deviations above the mean GFR decline and can therefore be used to identify patients with rapid functional decline 265 . Multiple studies have been undertaken to identify clinical, biochemical and genetic markers that can detect rapid progressors. Recent studies indicate that, in the stage 3-5 CKD group, 4 variables -creatinine, proteinuria, phosphate and sex -have C-statistics of 0.91 to predict end-stage renal disease (ESRD) 267, 268 . This means that although it is interesting to identify new biomarkers, it will be challenging to meaningfully add to the identification of people who progress to ESRD, especially in disease conditions associated with proteinuria.
Levels of plasma soluble tumour necrosis factor receptor 1 (sTNFR1) and sTNFR2 may potentially be used as predictors of renal failure in patients with either type 1 or type 2 diabetes 83, 84, 269 . An association between increased circulating sTNFR levels and poor renal disease prognosis has also been observed in both immunoglobulin A (IgA) nephropathy and idiopathic membranous nephropathy 270, 271 . Data suggest that circulating sTNFRs could derive from exosomes shed into the plasma 85 ; however, the precise tissues and cells responsible for the increased circulating levels of sTNFRs remain unclear. Increased urinary excretion and blood levels of kidney injury molecule 1 (KIM1; also known as TIM1 and hepatitis A virus cellular receptor 1 (HAVCR1)) have been associated with acute kidney injury, IgA nephropathy and diabetic nephropathy 77, 78, 272 . KIM1 is relatively selectively expressed in liver and renal proximal tubule cells and appears to play a part in modulating T cell immunity [273] [274] [275] . Interestingly, treatment with the angiotensin receptor antagonist irbesartan reduces urinary KIM1 levels in patients with diabetic nephropathy 276 .
Notably, recent studies have demonstrated that plasma KIM1 levels also increase with acute kidney injury, and, importantly, plasma KIM1 levels are predictive of progression of CKD in patients with type 1 diabetes 272 . The predictive value of these plasma inflammatory markers supports potential involvement of specific inflammatory pathways in the pathogenesis of diabetic nephropathy.
Although the identification of rapid progressors is an important endeavour, some critically important questions remain to be addressed. First and most importantly: what drives rapid progression in these patients? Are the pathways that drive rapid progression the same as those that drive moderate or slow progression, just with an increased magnitude? Or is it the activation of different pathways that is responsible for rapid progression? Will trials actually benefit from enrichment strategies or will we be simply selecting for resistant, potentially less compliant patients, in whom intervention will make less of an impact?
understanding of the pathophysiology of the disease process. In some circumstances, biomarker-based target engagement can help to drive such study enrichment, as exemplified by the substantial impact of precision medicine approaches being implemented in the oncology field.
There is a growing appreciation of patient heterogeneity with respect to the rate of loss of renal function. Accordingly, efficient identification and enrolment of patients who are most likely to progress and benefit from the candidate therapeutic intervention remains a substantial challenge. Recent results of the large Chronic Renal Insufficiency Cohort (CRIC) have indicated that when using a general patient population it could take more than a decade to achieve hard end points used in clinical trials 48 . This has raised the question as to whether trials should be focused on a subset of patients who experience a more rapid kidney function decline, who are considered to be 'rapid progressors'
.
One key inclusion criterion used to enrich for CKD patients at high risk for progression has been a high level of proteinuria. Baseline proteinuria is a strong predictor of poor renal outcomes [251] [252] [253] . Furthermore, the extent of treatment-associated proteinuria reduction in Phase II studies was highly predictive of a favourable outcome 254, 255 . These observations have driven trials of new therapeutics to recruit patients with high baseline levels of proteinuria. However, with more widespread use of ACEI and ARB therapy, proteinuria levels are already decreased in many patients, and recruiting patients with overt proteinuria is increasingly challenging in the implementation of renal trials.
Furthermore, clinical experience working with patients with minimal change disease indicates that proteinuria can be reversible and is not always associated with progressive kidney function decline 256 . There are increasing numbers of patients with diabetic kidney disease who progress without developing overt albuminuria -perhaps owing to ACEI-or ARB-induced proteinuria reduction. More than a decade ago, a study showed that nearly 25% of patients do not follow the 'classic' paradigm for diabetic kidney disease progression, wherein microalbuminuria is followed by macroalbuminuria and progressive GFR decline 257 . The development of novel biomarkers that supplement proteinuria in predicting progression of renal disease in patients already taking an ACEI or an ARB comprises a new challenge for the renal research community. Recent studies indicate that levels of plasma inflammatory markers may have some predictive value 72, 73, 76 
Clinical trial end points. Traditional drug registration trial end points in kidney disease include doubling of the serum creatinine, initiation of renal replacement therapy (dialysis or transplant) or death. Using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, doubling of serum creatinine level is equivalent to a 57% decline in eGFR 258 
. Several recent studies have explored the predictive validity of using lesser eGFR decrements (that is, -30% or -40%) of ESRD events in CKD trials 7, [259] [260] [261] . These analyses support the strong predictive value of these intermediate eGFR decrements as surrogates of the currently accepted end points. Because there are greater numbers of these intermediate events, use of these surrogate end points could enable smaller and/or shorter trials 262 . However, adopting this design would have to match with the appropriate mechanism of action, as many drugs (ACEIs and ARBs) acutely reduce the GFR while providing protection from ESRD after a longer-term follow-up 32 .
Although the data supporting the use of these intermediate surrogates are clear, the acceptability of these end points to regulatory agencies and payers has not yet been tested. Ultimately, payers shoulder the disproportionate economic burden of patients with CKD as they transition onto dialysis; however, simply shifting the costs from dialysis (for treatment of ESRD) to pre-dialysis care is not an attractive proposition. New therapies will need to not only demonstrate a reduction in the number of ESRD events in the treated population, but also show that the number Although almost all current chronic kidney disease (CKD) treatment trials have used the serum creatinine-based estimated glomerular filtration rate (eGFR) to evaluate the beneficial effect of drugs 32 , several studies have shown that eGFR does not correlate perfectly with tracer-based measured GFR (mGFR) 277 . This correlation is thought to be particularly insufficient at higher GFR ranges, for which creatinine-based estimations perform very poorly. Several researchers therefore advocate the use of mGFR in clinical trials as a way to improve precision and thereby reduce cost 278 . However, although small, single-centre studies reported variable results 279, 280 , investigation of the Chronic Renal Insufficiency Cohort (CRIC) -a large multicentre trial that resembles most Phase III treatment studies 279, 281, 282 -showed that one-time measures of mGFR do not have stronger cross-sectional associations with concurrent metabolic consequences of decreased renal function (such as hyperphosphataemia or hyperkalaemia) than the eGFR 281 . These results indicate that, in this population, mGFR is not a superior surrogate for CKD. Similarly, longitudinal measures of mGFR were not more strongly associated with future clinical sequelae of decreased renal function than repeated measures of eGFR were 282 . Considering the cost, the laborious nature of measuring GFR and the invasiveness of such techniques, mGFR should ideally provide superior prediction of clinically relevant CKD outcomes compared with estimated measures of renal function. However, mGFR did not outperform eGFR in this study or others. Therefore, these results do not appear to support the use of mGFR to improve estimation of kidney function change at GFR levels below 60 ml per min per 1.73m 2 . Future studies might be needed to study the differences between eGFR and mGFR at higher GFR levels, however high-GFR groups are not typically targeted for intervention trials.
of patients that must be treated to prevent one patient per year from going on to dialysis justifies the cost of that therapy. Perhaps the medical community has grown accustomed to accepting the wrong type of CKD therapeutic -one that slows, but does not remit, disease.
Conclusions and future directions
The need for development of novel therapeutics for CKD has never been greater. Although mortality rates have been dropping for most disease conditions, the rate has actually increased for patients with CKD. No new drug has been registered for the treatment of CKD since 2001. However, recent research has identified several potential novel therapeutic targets, including inflammation, fibrosis, cellular metabolism, vascular alterations and podocyte alterations, with some related agents already undergoing Phase II and III clinical trials.
At present, most renal clinical trials continue to enrol patients with stage 3 CKD and a relatively high level of albuminuria, as these are patients who will probably reach the trial end point (death, dialysis or doubling of serum creatinine) the fastest. The SONAR study is the only study that uses a more individualized approach and enriches for patients that are more likely to respond to treatment and less likely to develop side effects 77, 263 . The targeted approach is only slowly gaining popularity. For example, drugs that target metabolism would probably need to be introduced early, which is a difficult issue as these trials require large cohorts studied for long durations 187 . Other strategies, such as targeting inflammation, are likely to be effective even in later stages of the disease 264 . Therapeutics that specifically target fibrosis but not albuminuria are especially challenging, as clinically validated biomarkers linked to decreased fibrosis are not available to assess efficacy in short-term Phase II studies
Once an individual drug exhibits clinical benefit by delaying the progression of functional decline, it will be crucial to determine whether drug combination strategies could achieve not only prevention but also remission. In this regard, combining haemodynamic targeting with metabolic targeting, podocyte-specific targeting and an anti-inflammatory drug might provide benefits above and beyond single-drug treatments.
Opportunities in the field of 'genetic medicine' are also emerging in the treatment of kidney disease. Two genetic diseases for which this represents a promising approach are polycystic kidney disease and kidney disease associated with a mutation in apolipoprotein L1 (APOL1)
. Tailoring of specific therapy combinations towards these genetically defined diseases may help to optimize efficacy and reduce the number of patients needed to treat.
Cost remains a key limitation in the development of novel CKD therapies. Foremost among the development costs are the barriers to rapidly identifying and enrolling the appropriate patients into these trials. Patient registries and new trial designs may help to address some of the issues discussed above as well as validate novel trial end points. Adaptive clinical trial design -which evaluates patients' reactions to a drug beginning early in a clinical trial and modifies the trial in accordance with those findings -might also be beneficial in CKD. Indeed, according to industry estimation this design can reduce the cost of entering a drug to the market by two-thirds. The 'genetic revolution' has transformed several areas of medicine, of which oncology has seen the most prominent change. Large collaborative efforts, such as The Cancer Genome Atlas (TCGA), are enabling the systematic analysis of the genetics, genomics, epigenetics and proteomics of all cancer types, collecting hundreds of patient samples and associated clinical information 283 . Implementing such a collaborative team approach could be highly relevant for chronic kidney disease (CKD), which is unlikely to be a homogenous disease and in which diagnosis is almost exclusively based on clinical description. Although kidney biopsy is not performed on everyone with CKD, it appears to be increasingly safe and tissue samples are reasonably accessible.
Even though the size of the genetic effect is expected to be small in CKD, this does not mean that genetics of this disease do not highlight critically important and potentially targetable pathways. Two genetic diseases offer an important potential therapeutic opportunity in nephrology. The first is polycystic kidney disease, which is caused by a relatively common dominant mutation 284 . This mutation leads to epithelial cell proliferation and fluid secretion, causing a cystic appearance of the kidney. Arginine vasopressin and its second messenger cyclic AMP act as important promoters of cyst cell proliferation and fluid secretion into cysts 285 . Recent clinical studies indicate that treatment with tolvaptan, which is a vasopressin antagonist, shows some clinical benefit in patients with polycystic kidney disease 286 . The second disease of relevance is kidney disease associated with a mutation in APOL1, the gene encoding apolipoprotein L1. APOL1 mutations have a high allele frequency in the West African population and its diaspora, including African Americans. People with two risk alleles have a 3-100 times increased risk of developing CKD, indicating a strong effect size and further highlighting its clinical significance 287 .
As of yet, studies have been unable to demonstrate increased disease risk in patients with only a single APOL1 risk allele, indicating a recessive mode of inheritance 265, 287 . Although most recessive mutations are loss-of-function variants, people who have APOL1-null mutations are phenotypically normal and do present with kidney disease 288 , suggesting a recessive gain-of-function variant. Although the mechanism of APOL1-induced cytotoxicity remains to be explored, we are presented with a unique therapeutic opportunity, whereby simply reducing APOL1 levels would likely be associated with therapeutic benefit. In this aspect it is important to understand the transcriptional regulation of APOL1. APOL1 appears to be part of the innate immune system and transcriptionally regulated by interferons and bacterial toxins 289 . As compounds that target immune pathways are already in clinical development, some of these could potentially be repurposed for APOL1-associated kidney disease.
APOL1-associated kidney disease
Kidney disease caused by genetic variants (G1 and G2) in the apolipoprotein L1 gene that are present in close to one-third of African Americans. These mutations are associated with a several-fold increase in chronic kidney disease and end-stage renal disease but protect from African sleeping sickness.
In summary, care of patients with CKD is emerging as one of the most costly and rapidly increasing disease burdens facing society. Although drug development for CKD has lagged behind other therapeutic areas, recent activity in this area has increased, owing in part to recog nition of this unmet medical need. Nevertheless, systemic engagement of the pharmaceutical industry has been lacking, partly owing to lack of success, operational difficulties (for example, slow patient enrolment) and long-duration outcomes trials. Early patient-centric discovery approaches and broad academic, industry and patient advocacy partnerships can provide avenues to enhance patient therapeutic response, patient and physician disease awareness, and improve clinical trial efficiencies. Integrated engagement of scientists and stakeholders across the range of medical delivery and payer systems is achievable but crucial to stem the tide of kidney disease in the twenty-first century.
